Oral Mini Pulse Dexamethasone in Pediatric Vitiligo

Summary

The goal of this clinical trial is to learn if oral mini pulse (OMP) dexamethasone works to treat active vitiligo in children and also learn about the safety of this drug within this age group the main questions it aims to answer are does OMP halt activity in active vitiligo and what medical problems patients might experience while using the drug with special attention to linear growth. Researchers will give OMP dexamethasone to participating patients to see if the drug works to treat active vitiligo and whether it has any effect on linear growth. Participants will take OMP dexamethasone two fixed days per week for a period of 3 months. before starting treatment, patients will do baseline evaluation and investigations then monthly evaluation to monitor progress, report any side effects at the end of treatment period response to drug, lab values and growth will be evaluated then final evaluation of growth will be done after stoppage of drug.

Timeline

Start

2026-02-28

Primary completion

2026-07

Completion

2026-07

Publications

• Background Nicolaidou E, Mastraftsi S, Tzanetakou V, Rigopoulos D. Childhood Vitiligo. Am J Clin Dermatol. 2019 Aug;20(4):515-526. doi: 10.1007/s40257-019-00430-0.
• Background Lobato-Berezo A, March-Rodriguez A, Grimalt R, Rodriguez-Lomba E, Seto-Torrent N, Pujol RM, Ruiz-Villaverde R. Mini pulse corticosteroid therapy with oral dexamethasone for moderate to severe alopecia areata: A multicentric study. Dermatol Ther. 2022 Nov;35(11):e15806. doi: 10.1111/dth.15806. Epub 2022 Sep 16.
• Background Sinha P, Sood A, Mukherjee B, Sinha A, Baveja S, Pathania V. Study to evaluate effect of oral mini pulse corticosteroid therapy for unstable vitiligo on hypothalamic pituitary adrenal axis suppression. Med J Armed Forces India. 2024 Dec;80(Suppl 1):S66-S72. doi: 10.1016/j.mjafi.2022.08.010. Epub 2022 Oct 22.
• Background Majid I, Masood Q, Hassan I, Khan D, Chisti M. Childhood vitiligo: response to methylprednisolone oral minipulse therapy and topical fluticasone combination. Indian J Dermatol. 2009;54(2):124-7. doi: 10.4103/0019-5154.53185.
• Background Radakovic-Fijan S, Furnsinn-Friedl AM, Honigsmann H, Tanew A. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol. 2001 May;44(5):814-7. doi: 10.1067/mjd.2001.113475.
• Background Kanwar AJ, Mahajan R, Parsad D. Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo. J Cutan Med Surg. 2013 Jul-Aug;17(4):259-68. doi: 10.2310/7750.2013.12053.
• Background Kanwar AJ, Dhar S, Dawn G. Oral minipulse therapy in vitiligo. Dermatology. 1995;190(3):251-2. doi: 10.1159/000246705. No abstract available.
• Background Pasricha JS, Khaitan BK. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol. 1993 Oct;32(10):753-7. doi: 10.1111/j.1365-4362.1993.tb02754.x.
• Background El Ghazaly, G. M., Albalat, W. M. and El Ghareeb, M. I. (2021) 'Use of oral mini pulse dexamethasone in vitiligo patients: Review article', Egyptian Journal of Hospital Medicine, 85(2), pp. 3909-3911. doi: 10.21608/ejhm.2021.205395.

Drugs

Indications